Company news
Phio Pharmaceuticals Corp. news in 2026
Phio Pharmaceuticals Corp.'s news releases, calls and decks from 2026, newest first.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
October 19, 2026
Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
October 13, 2026
Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026
October 6, 2026
Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference
October 5, 2026
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
September 23, 2026
Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
September 14, 2026
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 11, 2026
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894
August 11, 2026
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
August 6, 2026
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
July 22, 2026
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors
July 21, 2026
Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision
July 15, 2026
Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026
June 25, 2026
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762
June 24, 2026
Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026
June 18, 2026
Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026
May 12, 2026
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
May 7, 2026
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
April 13, 2026
Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026
April 8, 2026
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
March 29, 2026
Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement
March 22, 2026
Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office
March 15, 2026
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT
March 9, 2026
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT
March 9, 2026
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update
March 4, 2026
Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company
February 22, 2026
Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894
February 19, 2026
Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial
February 10, 2026
Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference
January 26, 2026
Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial
January 20, 2026
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026
January 15, 2026